Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy

Breast cancer patients often receive systemic drugs as the initial curative treatment of their disease. The initial systemic therapy leads to a variable degree of tumor shrinkage. At present, there is no evidence-based consensus among breast surgeons on the optimal extent of resection after considerable tumor shrinkage and whether resection margin should be designed according to the tumor extent before treatment or the extent after treatment. This trial will help determine the optimal extent of resection in tumors that exhibits a significant change in volume after primary systemic therapy.

NCT Number	NCT03417622
Lead Sponsor	Mansoura University
Conditions	Breast Cancer
Enrollment	370 participants
Start Date	2019-08-01
Primary Completion	2026-08-01 (estimated)
Study Completion	2026-08-01 (estimated)
Updated on ClinicalTrials.gov	2021-02-25